Study guide
10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics
National Certified Peer Recovery Support Specialist NCPRSS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction to the NCPRSS Examination
1.1 NCPRSS Exam Structure, Credentialing, and Eligibility 1.2 Study Framework, Exam Strategies, and Navigating Test Scenarios
2 Chapter 2: Foundations of the Peer Recovery Support Role
2.1 Defining the Peer Role: Lived Experience and Mutuality 2.2 Scope of Practice and Non-Clinical Role Boundaries 2.3 Differentiating the Peer Specialist from Clinical and Support Roles
3 Chapter 3: Peer Engagement, Advocacy, Intake, and Service Coordination
3.1 Relationship Building and Active Listening in Peer Work 3.2 Individual and Systems-Level Peer Advocacy 3.3 Community Resource Navigation and Connection 3.4 Screening and Intake: The Peer's Role at First Contact 3.5 Recognizing Indicators of Substance Use and Co-Occurring Disorders for Referral 3.6 Case Management and Service Coordination in Peer Practice
4 Chapter 4: Cultural Humility, Trauma-Informed Peer Support, and Self-Care
4.1 Cultural Humility and Diversity in Peer Support 4.2 Trauma-Informed Peer Principles and Safety 4.3 Peer Specialist Self-Care and Burnout Prevention 4.4 Reflective Supervision and Professional Growth
5 Chapter 5: Recovery Paradigms, Definitions, and Recovery Capital
5.1 Definitions, Principles, and Dimensions of Recovery 5.2 Recovery-Oriented Systems of Care (ROSC) 5.3 Recovery Capital Assessment and Growth
6 Chapter 6: Stages of Change and Motivational Interviewing in Peer Support
6.1 The Transtheoretical Model: Stages of Change 6.2 Motivational Interviewing Spirit and Principles 6.3 Core MI Communication Skills: OARS and Change Talk
7 Chapter 7: Diverse Pathways to Recovery
7.1 Mutual Aid and 12-Step Pathways 7.2 Secular, Cognitive, and Faith-Based Pathways 7.3 Harm Reduction and Medication-Assisted Pathways
8 Chapter 8: Person-Centered Recovery Planning and Crisis Support
8.1 Person-Centered Goal Setting and Strengths Assessment 8.2 Wellness Recovery Action Planning (WRAP) and Recovery Plans 8.3 De-escalation and Crisis Intervention in Peer Practice 8.4 Suicide Risk Recognition, Safety Planning, and 988 Lifeline
9 Chapter 9: Recovery Documentation, Communication, and Recurrence Support
9.1 Peer Documentation and Record Keeping Standards 9.2 Lapse, Relapse, and Recurrence Management 9.3 Family Systems and Peer Support for Loved Ones
10 Chapter 10: Addiction Neurobiology and Substance Classes
10.1 Neurobiology of Addiction and the Brain Reward System 10.2 Central Nervous System Depressants and Stimulants 10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics
11 Chapter 11: Medications, Overdose Response, and Infectious Disease Prevention
11.1 Medications for Opioid Use Disorder (MOUD) 11.2 Medications for Alcohol and Tobacco Use Disorders 11.3 Overdose Recognition, Naloxone Administration, and Post-Reversal Care 11.4 HIV, Viral Hepatitis, and Other Pathogens: Prevention, Testing, and Linkage
12 Chapter 12: Ethical Standards and Professional Boundaries
12.1 NAADAC/NCC AP Code of Ethics and Peer Standards 12.2 Dual Relationships, Power Dynamics, and Boundaries 12.3 Managing Conflicts of Interest and Personal Conduct
13 Chapter 13: Legal Regulations, Confidentiality, and Mandated Reporting
13.1 Federal Confidentiality Laws: 42 CFR Part 2 and HIPAA 13.2 Exceptions to Confidentiality and Permitted Disclosures 13.3 Mandated Reporting and Duty to Warn/Protect
14 Chapter 14: Peer Rights, Informed Consent, and Credential Maintenance
14.1 Peer Rights, Autonomy, and Informed Consent 14.2 NCPRSS Credential Maintenance, Renewal, and Professional Development
10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics
Key Takeaways Explain This Topic AI
Opioids produce analgesia, sedation, and euphoria through mu-opioid receptor agonism, but carry fatal overdose mortality through central respiratory depression in the brainstem.
While opioid withdrawal is intensely miserable (flu-like symptoms, piloerection, vomiting, diarrhea), it is rarely fatal on its own; however, the subsequent loss of physiological tolerance during abstinence makes post-treatment recurrence the single greatest risk factor for fatal overdose.
Cannabis interacts with CB1 and CB2 receptors in the endocannabinoid system; chronic high-potency use can lead to Cannabis Use Disorder, a distinct withdrawal syndrome, and Cannabis Hyperemesis Syndrome (CHS), with cyclic vomiting that hot showers often temporarily relieve.
Dissociatives like Ketamine and PCP antagonize NMDA glutamate receptors, producing sensory detachment; PCP carries extreme risks of combative agitation, nystagmus, and profound analgesia where individuals cannot feel physical pain.
Emerging synthetics represent lethal shifts in the illicit drug supply: ultra-potent nitazenes and veterinary sedatives like Xylazine ('tranq') cause severe necrotic skin ulceration and profound non-opioid sedation that is unresponsive to naloxone, necessitating aggressive rescue breathing and harm reduction.
Last updated: October 2026
10.3 Opioids, Cannabis, Hallucinogens, and Emerging Synthetics
Note
Quick Answer: The modern illicit drug landscape encompasses diverse chemical classes, each presenting unique neurobiological mechanisms and safety profiles. Opioids act as agonists at mu-opioid receptors , carrying fatal overdose risks via brainstem respiratory depression ; while opioid withdrawal is excruciatingly miserable (flu-like symptoms, piloerection, nausea), its primary danger is the rapid loss of physiological tolerance , which makes a post-abstinence recurrence exceptionally lethal. Cannabis acts upon the endocannabinoid system (CB1/CB2 receptors) and can induce Cannabis Hyperemesis Syndrome (CHS) with chronic high-potency use. Dissociatives like PCP and Ketamine block NMDA glutamate receptors , causing sensory detachment, numbness, and potential behavioral emergencies. Crucially, emerging synthetics like Nitazenes and the non-opioid veterinary tranquilizer Xylazine ('tranq') present unprecedented overdose lethality, severe necrotic skin ulcerations , and deep sedation that does not respond to naloxone , making rescue breathing and comprehensive harm reduction paramount.
Opioids: Classification, Mechanisms, and Mortality Risks
Opioids are natural, semi-synthetic, or synthetic substances that bind to specific opioid receptors in the central and peripheral nervous systems, as well as the gastrointestinal tract. They are classified into three distinct categories based on their origin: ┌────────────────────────────────────────────────────────────────────────┐
- │ CLASSIFICATION OF OPIOID COMPOUNDS │
- ├──────────────────┬─────────────────────────────────────────────────────┤
- │ CATEGORY │ REPRESENTATIVE SUBSTANCES │
- ├──────────────────┼─────────────────────────────────────────────────────┤
- │ 1. Natural │ • Morphine, Codeine │
- │ Opiates │ • Directly derived from the opium poppy resin │
- │ │ (Papaver somniferum) │
- ├──────────────────┼─────────────────────────────────────────────────────┤
- │ 2. Semi-Synthetic│ • Heroin (diacetylmorphine), Oxycodone (OxyContin, │
- │ Opioids │ Percocet), Hydrocodone (Vicodin), Hydromorphone │
- │ │ (Dilaudid), Oxymorphone (Opana), Buprenorphine │
- │ │ • Synthesized by chemically modifying natural opiates│
- ├──────────────────┼─────────────────────────────────────────────────────┤
- │ 3. Fully │ • Fentanyl, Carfentanil, Methadone, Meperidine │
- │ Synthetic │ (Demerol), Tramadol │
- │ Opioids │ • Completely manufactured in laboratories from base │
- │ │ chemical precursors; no poppy base utilized │
- └──────────────────┴─────────────────────────────────────────────────────┘
- Mechanism of Action: The Mu-Opioid Receptor and Respiratory Suppression
There are three primary opioid receptor subtypes in the human body: Mu ( μ \mu μ ) , Delta ( δ \delta δ ) , and Kappa ( κ \kappa κ ) . The rewarding, analgesic, and lethal properties of opioids are governed primarily by the Mu-opioid receptor :
Analgesia & Euphoria : Mu receptors are dense in pain-modulating regions such as the periaqueductal gray of the midbrain and the dorsal horn of the spinal cord (blocking incoming pain signals) and on inhibitory GABA interneurons in the Ventral Tegmental Area (VTA). By inhibiting GABA, opioids "disinhibit" dopamine neurons, allowing a powerful torrent of dopamine to flood the Nucleus Accumbens.
Lethal Respiratory Depression : Mu-opioid receptors are also concentrated in the respiratory rhythm-generating centers of the brainstem (specifically the pre-Bötzinger complex in the ventrolateral medulla). Agonism at these receptors blunts the brainstem's sensitivity to rising levels of carbon dioxide ( C O 2 CO_2 C O 2 ) in the blood. In an overdose, the autonomic drive to breathe ceases, leading to respiratory arrest, anoxic brain injury, and death.
The Classic Opioid Overdose Triad
When evaluating an unconscious individual for acute opioid overdose, the clinical presentation is defined by the Opioid Overdose Triad :
Pinpoint Pupils (Miosis) : Pupils constricted to tiny points (unless severe anoxia has set in, which can cause terminal dilation).
Severe Respiratory Depression : Slow, shallow breathing ( < 8 <8 < 8 breaths per minute), agonal breathing (gasping/snoring sounds), or total apnea.
Unresponsiveness / Coma : Flaccid muscle tone, inability to be aroused by verbal or physical stimulation (such as a sternal rub), and cyanosis (bluish or grayish discoloration of lips and nail beds).
Opioid Withdrawal: The Agonizing Misery and the Loss-of-Tolerance Trap
Unlike alcohol or benzodiazepine withdrawal, uncomplicated opioid withdrawal is rarely fatal for an otherwise healthy adult. However, it is subjectively agonizing and deeply traumatizing. Clinical tools like the Clinical Opiate Withdrawal Scale (COWS) measure its signature symptoms:
Early Opioid Withdrawal Signs (6 to 18 Hours) Peak Opioid Withdrawal Signs (24 to 72 Hours)
Watery eyes (lacrimation) and runny nose (rhinorrhea); excessive yawning and profuse sweating (diaphoresis); restlessness, severe anxiety, and insomnia; dilated pupils (mydriasis) and muscle twitches Severe abdominal cramps, nausea, and projectile vomiting; watery, persistent diarrhea (risk of acute dehydration); gooseflesh / piloerection (origin of "cold turkey"); involuntary leg kicking (origin of "kicking the habit"); severe, deep bone and muscle aches
Caution
THE FATAL TRAP OF LOST TOLERANCE: When an individual achieves abstinence—whether through a 30-day inpatient stay, incarceration, medical detox, or personal recovery—their physiological tolerance to opioids drops precipitously within days to weeks . If the individual experiences a recurrence and injects or consumes the same dosage they used prior to abstinence, their brainstem cannot tolerate the concentration. Post-discharge and post-incarceration periods represent the single highest statistical mortality window for fatal opioid overdoses.
Cannabis and the Endocannabinoid System
Cannabis is the most widely used psychoactive substance globally after alcohol and caffeine. It acts directly upon the human Endocannabinoid System (ECS) , an intricate regulatory neuromodulatory network that oversees mood, appetite, sleep, pain sensation, and immune response.
Endogenous Ligands : The body synthesizes its own cannabinoids on demand, primarily Anandamide (often called the "bliss molecule") and 2-Arachidonoylglycerol (2-AG) .
Receptor Subtypes :
CB1 Receptors : Concentrated densely in the central nervous system (cerebral cortex, hippocampus, basal ganglia, and cerebellum). Governs psychoactive effects, cognition, memory, motor coordination, and pain.
CB2 Receptors : Concentrated primarily in the peripheral nervous system and immune cells (spleen, tonsils, white blood cells). Modulates inflammation and immune function without causing intoxication.
Phytocannabinoids: THC vs. CBD
Delta-9-Tetrahydrocannabinol (THC) : The primary psychoactive constituent. Acts as a partial agonist at CB1 receptors, producing euphoria, relaxation, altered sensory perception, increased appetite ("munchies"), and transient short-term memory impairment. High doses can trigger acute panic, paranoia, and transient psychosis.
Cannabidiol (CBD) : A non-intoxicating compound. Demonstrates low direct affinity for CB1/CB2 receptors, acting instead as a negative allosteric modulator and interacting with serotonin (5-HT1A) and vanilloid receptors to provide anxiolytic and anti-inflammatory effects.
Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome
Despite the common public misconception that cannabis is entirely non-addictive, the DSM-5 formally recognizes Cannabis Use Disorder . Approximately 10% to 30% of regular cannabis users develop psychological or physical dependence. Furthermore, Cannabis Withdrawal Syndrome is clinically established, presenting within 24 to 72 hours of cessation with:
- Irritability, anger, or aggressive mood swings
- Nervousness and anxiety
- Severe sleep difficulty and vivid, bizarre dreams
- Decreased appetite and weight loss
- Physical symptoms: abdominal pain, shakiness, sweating, fever, or chills
- Cannabis Hyperemesis Syndrome (CHS)
A severe clinical consequence of long-term, high-potency daily cannabis use is Cannabis Hyperemesis Syndrome (CHS) . Paradoxically, while cannabis is medically recognized for anti-emetic properties at low doses, chronic hyper-stimulation of CB1 receptors in the enteric nervous system deranges gastrointestinal motility:
Clinical Presentation : Cyclical, intractable nausea, persistent profuse vomiting, and severe colicky abdominal pain.
The Hallmark Diagnostic Behavioral Clue : Sufferers develop a compulsive, ritualistic need for prolonged, scalding hot baths or showers , which transiently alleviates nausea by activating TRPV1 vanilloid receptors and redistributing cutaneous blood flow.
Resolution : CHS often responds poorly to standard anti-emetic medications (e.g., ondansetron), and emergency clinicians may use other treatments for acute episodes. The definitive treatment is stopping cannabis use ; symptoms typically return if use resumes.
Hallucinogens and Dissociatives
Hallucinogens and dissociatives represent distinct classes of substances that fundamentally alter sensory perception, cognition, and awareness of reality. ┌────────────────────────────────────────────────────────────────────────┐
- │ HALLUCINOGENS VS. DISSOCIATIVE SUBSTANCES │
- ├──────────────────────────┬─────────────────────────────────────────────┤
- │ CLASS & SUBSTANCES │ PHARMACOLOGICAL TARGET & CLINICAL PROFILE │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Classic Psychedelics │ • 5-HT2A Serotonin Receptor Agonists │
- │ (Psilocybin, LSD, │ • Profound perceptual distortions, visual │
- │ Mescaline, DMT) │ hallucinations, synesthesia ("seeing │
- │ │ sounds"), mystical/ego-dissolution states│
- │ │ • Low physiological toxicity; high risk of │
- │ │ psychological panic ("bad trip") and HPPD │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Entactogens / Empathogens│ • Massive Serotonin & Dopamine Releaser │
- │ (MDMA / Ecstasy / Molly) │ • Heightened empathy, emotional closeness, │
- │ │ sensory enhancement │
- │ │ • Acute medical risks: severe hyperthermia, │
- │ │ severe hyponatremia (water toxicity) │
- ├──────────────────────────┼─────────────────────────────────────────────┤
- │ Dissociative Anesthetics │ • NMDA Glutamate Receptor Antagonists │
- │ (Ketamine, Phencyclidine │ • Sensory detachment from body and physical │
- │ [PCP], Dextromethorphan)│ environment; profound analgesia (numbness)│
- │ │ • PCP Risks: Extreme combative agitation, │
- │ │ rotary nystagmus, self-inflicted trauma │
- │ │ due to inability to register pain │
- └──────────────────────────┴─────────────────────────────────────────────┘
- Phencyclidine (PCP) and Ketamine Nuances
Peer specialists working in emergency departments or street outreach must understand the extreme behavioral risks associated with Phencyclidine (PCP, "Angel Dust") :
NMDA Blockade : Blocks excitatory glutamate signaling, disconnecting the conscious mind from somatic sensory inputs.
Symptom Triad : Intense, volatile agitation, vertical/rotary nystagmus (eyes rapidly jerking horizontally or vertically), and complete physical analgesia .
Safety Hazard : Because PCP completely abolishes physical pain perception, individuals can break bones, sever tendons, or suffer deep lacerations without feeling discomfort, often struggling against physical obstacles with seemingly superhuman force. De-escalation requires a calm, low-stimulation environment with non-threatening body positioning.
Emerging Synthetic Threats: Fentanyl Analogs, Nitazenes, and Xylazine
The illicit drug market in North America has undergone a catastrophic structural transition from plant-derived compounds (heroin, cocaine) to ultra-potent, low-cost synthetic adulterants.
1. Illicitly Manufactured Fentanyl (IMF) and Ultra-Potent Analogs
Unlike pharmaceutical transdermal fentanyl patches, Illicitly Manufactured Fentanyl (IMF) is synthesized in clandestine labs and pressed into counterfeit prescription pills (e.g., fake "M30" oxycodone pills, counterfeit Xanax) or mixed into powder supplies.
Potency : Fentanyl is about 50 to 100 times more potent than morphine and roughly 50 times more potent than heroin (CDC; DEA). The DEA considers 2 milligrams, about the size of a few grains of salt, a potentially lethal dose.
Carfentanil : A veterinary opioid for sedating large animals, about 10,000 times more potent than morphine (DEA); even tiny amounts in the drug supply are extremely dangerous to the person who uses them.
Rapid Onset ("Wooden Chest Syndrome") : Rapid, high-dose fentanyl exposure can cause chest wall and vocal cord rigidity that makes rescue breathing difficult; give naloxone promptly and get EMS on the way.
2. Nitazenes (Synthetic Benzimidazole Opioids)
As regulatory scrutiny restricted fentanyl precursors, illicit chemists developed Nitazenes (e.g., Isotonitazene, Metonitazene, Protonitazene). These synthetic opioids have no approved human medical use in the United States:
Variable, Often Extreme Potency : Potency differs widely between nitazenes; some (such as etonitazene and N-pyrrolidino etonitazene) are estimated to be several times more potent than fentanyl, while others are similar to or weaker than fentanyl. Users rarely know which one they have.
Naloxone Requirements : Due to exceptionally high receptor binding affinity, nitazene overdoses frequently require multiple successive doses of naloxone combined with prolonged rescue breathing.
3. Xylazine ("Tranq" / "Tranq Dope")
Xylazine is a non-opioid pharmaceutical drug developed solely as a veterinary sedative, analgesic, and muscle relaxant for large animals (horses, cattle). It is not approved for human use .
Xylazine has emerged as a pervasive adulterant in the illicit fentanyl supply, particularly throughout the Eastern and Midwestern United States, creating a lethal combination known on the street as "Tranq Dope." ┌────────────────────────────────────────────────────────────────────────┐
- │ THE CLINICAL CRISIS OF XYLAZINE │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 1. NON-OPIOID MECHANISM │
- │ Central Alpha-2 Adrenergic Agonist (similar to clonidine) │
- │ • Inhibits norepinephrine release in the brainstem │
- │ • Causes profound sedation, bradycardia, severe hypotension │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 2. NALOXONE NON-RESPONSIVENESS │
- │ • Xylazine is NOT an opioid! Naloxone does NOT reverse xylazine. │
- │ • However: Overdoses involve BOTH fentanyl and xylazine! │
- │ • ACTION: ALWAYS administer Naloxone to reverse the opioid, and │
- │ IMMEDIATELY initiate RESCUE BREATHING for xylazine sedation. │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 3. SEVERE NECROTIC SKIN ULCERATION │
- │ • Causes severe peripheral vasoconstriction and localized ischemia │
- │ • Produces horrific necrotic ulcers with black eschar, slough, and │
- │ exposed bone/muscle that occur ANYWHERE on the body (not just at │
- │ injection sites; occurs even with snorting or smoking). │
- │ • High risk of osteomyelitis, systemic sepsis, and limb amputation. │
- └────────────────────────────────────────────────────────────────────────┘
Caution
XYLAZINE EMERGENCY OVERDOSE PROTOCOL: When an individual overdoses on "tranq dope," administering naloxone will restore their breathing by displacing fentanyl from the mu-opioid receptors, but the person will often remain deeply unconscious and unresponsive due to the xylazine sedation .
Peer specialists must NOT continue endlessly pumping dozens of naloxone doses into an individual who has already resumed breathing! Doing so will precipitate violent precipitated opioid withdrawal without waking the person from the xylazine stupor. If breathing is adequate, place the person in the recovery position, monitor breathing and airway, and wait for EMS; if breathing is inadequate, give rescue breaths.
Peer Harm Reduction Navigation
Peer specialists operate at the cutting edge of evidence-based Harm Reduction , meeting individuals where they are without judgment to preserve life until recovery is chosen:
Drug Checking Technology : Providing Fentanyl Test Strips (FTS) and Xylazine Test Strips (XTS) , educating peers on proper dilution techniques to avoid false positives/negatives.
Never Use Alone Protocols : Promoting the "Never Use Alone" national overdose prevention hotline (peer-operated hotline that stays on the phone while an individual uses and dispatches EMS only if the person becomes unresponsive).
Rescue Breathing Priority : In the era of synthetic adulterants, rescue breathing (1 breath every 5 seconds) is the single most critical life-saving physical intervention a peer can perform alongside naloxone.
Wound Care Navigation : Connecting peers suffering from xylazine-induced necrotic ulcerations to barrier-free medical clinics, providing clean dressing supplies, sterile saline, and non-judgmental wound management support to prevent sepsis and amputation.